BRAF and metastatic melanoma: A combination of a BRAF and a MEK inhibitor (BRAFi/MEKi-combined targeted therapy) has revolutionized the management of metastatic melanoma patients harboring a BRAF mutation at codon 600, significantly improving their overall survival (OS) and progression-free survival (PFS) [8].